New Australian drug shows positive response in patients with multiple myeloma blood cancer
The trial expansion in Australia follows a positive review of safety and efficacy data by an independent Data Monitoring Committee (DMC) of data from the first six patients treated with the new monoclonal antibody therapy at The Alfred Hospital in Melbourne under the supervision of principal investigator and head of Malignant Haematology and Stem Cell Transplantation, Professor Andrew Spencer.
The DMC recommended that recruitment under the trial be expanded to include up to 27 patients suffering from the life threatening disease multiple myeloma.
The promising new drug, called MDX-1097, is a genetically engineered antibody that binds specifically to a target protein found on the cell surface of some types of blood cancer. Researchers anticipate the antibody will potentially reduce the number of cancerous cells in multiple myeloma patients and improve patient health and wellbeing. Laboratory studies have shown that the antibody works with the patient’s immune system to induce death of their multiple myeloma cancer cells.
Most read news
Organizations
Other news from the department research and development
Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous